Mucosal and systemic immunization against tuberculosis by ISCOMATRIX nano adjuvant co-administered with alginate coated chitosan nanoparticles

Document Type : Original Article


1 Clinical Microbiology Laboratory, Fatemieh hospital, Hamadan University of Medical Science, Hamedan, Iran

2 Department of Microbiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran

3 Immunology Research Center, Bu Ali Research Institute, Mashhad University of Medical Science, Mashhad, Iran

4 Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

5 Department of Laboratory Sciences, School of Allied Medical Sciences, Ahavz Jundishapur University of Medical Sciences, Ahvaz, Iran

6 Nanotechnology Research center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): BCG vaccine has no longer been appreciated to immunize against tuberculosis, worldwide, so novel appropriate adjuvants have been dedicated to improve immune responses. This study aimed to evaluate the immunomodulatory effects of ISCOMATRIX as an adjuvant to stimulate potent humoral and cellular immune responses of the PPE17 loaded alginate coated nanoparticles through subcutaneous and intranasal vaccination. 
Materials and Methods: Size, polydispersity index, and morphology of the resulting colloidal particles were explored by dynamic light scattering (DLS). The cellular and/or humoral immune stimulation properties of ISCOMATRIX adjuvant were measured by measuring the level of IFNγ, IL-4, IL-17, and TGFβ in spleen cell cultures and IgG1 and IgG2a in serum and sIgA in nasal lavage of immunized mice, respectively. 
Results: The spherical cage-like particles of ISCOMATRIX adjuvant have optimal size of 59±6 nm appropriate for an immune adjuvant vaccine. ISCOMATRIX induced robust Th1 (IFN-γ) and IL-17 cytokine response also significant IgG2a and IgG1antibodies in both subcutaneous and intranasal routes and elicited mucosal sIgA response when administered intranasally. As a booster for BCG, ISCOMATRIX induced immune responses only in subcutaneous route. 
Conclusion: These findings indicate that ISCOMATRIX is a promising adjuvant with the potential for increasing cellular and humoral immunity both after subcutaneous and intranasal administration. 


Main Subjects

1. World Health Organization. Global TB report 2021. Geneva: World Health Organization, 2021.
2. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global tuberculosis report 2020 - reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis 2021; 113 Suppl 1:S7-S12.
3. Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2018; 39:271-285.
4. Abrahem R, Chiang E, Haquang J, Nham A, Ting Y-S, Venketaraman V. The role of dendritic cells in TB and HIV infection. J Clin Med 2020; 9:1-15.
5. Stewart E, Triccas JA, Petrovsky N. Adjuvant strategies for more effective tuberculosis vaccine immunity. Microorganisms 2019; 7:1-16.
6. Pearse MJ, Drane D. ISCOMATRIX adjuvant: A potent inducer of humoral and cellular immune responses. Vaccine 2004; 22:2391-2395.
7. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991; 146:431-437.
8. Baz Morelli A, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935-943.
9. Pearse MJ, Drane D. ISCOMATRIX® adjuvant for antigen delivery. Adv Drug Deliv Rev 2005; 57:465-474.
10. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761-772.
11. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005; 105:2465-2472.
12. Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 2009; 182:1253-1259.
13. Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012; 90:540-552.
14. Boyle J, Eastman D, Millar C, Camuglia S, Cox J, Pearse M, et al. The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 2007; 25:2541-2544.
15. Najafi A, Ghazvini K, Sankian M, Gholami L, Amini Y, Zare S, et al. T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration. Life Sci 2021; 282:119806.
16. Dehghan S, Kheiri MT, Tabatabaiean M, Darzi S, Tafaghodi M. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res 2013; 36:981-992.
17. Dehghan S, Tafaghodi M, Bolourieh T, Mazaheri V, Torabi A, Abnous K, et al. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants. Int J Pharm 2014; 475:1-8.
18. Copland MJ, Rades T, Davies NM. Hydration of lipid films with an aqueous solution of Quil A: A simple method for the preparation of immune-stimulating complexes. Int J Pharm 2000; 196:135-139.
19. Mosafer J, Badiee A, Mohammadamini Z, Komeilinezhad A, Tafaghodi M. Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles. Artif Cells Nanomed Biotechnol 2018; 46:587-593.
20. Malik A, Gupta M, Mani R, Bhatnagar R. Single-dose Ag85B-ESAT6-loaded poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis. Int J Nanomedicine 2019; 14:3129-3143.
21. Da Fonseca D, Frerichs J, Singh M, Snippe H, Verheul A. Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine 2000; 19:122-131.
22. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infec Immun 2007; 75:408-416.
23. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011; 187:55-63.
24. Hu K, Elvander M, Merza M, Åkerblom L, Brandenburg A, Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 1998; 113:235-243.
25. Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 2013; 3:100-109.
26. Gupta PN. Mucosal vaccine delivery and M cell targeting.  Targeted Drug Delivery: Concepts and Design: Springer; 2015. p. 313-337.
27. Sjölander A, Cox JC, Barr IG. ISCOMs: An adjuvant with multiple functions. J Leukoc Biol 1998; 64:713-723.